TellWell
…
← Misinformation tracker
UnverifiableNews · Health

Yes, a Trial of 200,000+ Women in Africa Did Show a Major Drop in Severe Bleeding — Here's What Actually Happened

“A large-scale trial involving over 200,000 women across Nigeria, Kenya, Tanzania, and South Africa tested an integrated approach that resulted in a marked decrease in severe bleeding cases”

The argument in brief

A claim circulating in global health circles describes a large trial across Nigeria, Kenya, Tanzania, and South Africa that cut severe postpartum bleeding cases dramatically. This is accurate. The E-MOTIVE trial, published in The Lancet in 2023, enrolled over 210,000 women and found roughly a 60% reduction in severe postpartum hemorrhage using a bundled care approach.

The numbersE-MOTIVE Trial: Severe PPH Outcomes (Intervention vs. Control)

Data: E-MOTIVE Trial, The Lancet, 2023

Why it spread

People shared this because it represents rare, concrete progress on a problem — maternal death from bleeding — that has resisted easy solutions for decades. Global health advocates and medical professionals were genuinely excited, and the story was picked up widely because the results were both dramatic and credible. Positive, evidence-backed health news from Africa also tends to get amplified by those working to counter narratives that only highlight crisis.

The claim is true. A landmark trial tested an integrated approach to postpartum hemorrhage — dangerous bleeding after childbirth — across 78 hospitals in Nigeria, Kenya, Tanzania, and South Africa, involving more than 200,000 women. The results were striking: severe bleeding cases fell by around 60% compared to standard care.

The trial is called E-MOTIVE, and its results were published in The Lancet in 2023. The intervention wasn't a single drug or device — it was a bundle. Clinicians used a blood-collection drape to detect heavy bleeding early, then immediately applied a package of treatments: uterotonic drugs to contract the uterus, uterine massage, IV fluids, and a physical examination. Speed and coordination were the core idea.

The numbers back it up clearly. In hospitals using standard care, about 4.3% of women experienced severe postpartum hemorrhage. In hospitals using the E-MOTIVE bundle, that figure dropped to 1.6%. Independent analyses reported by NEJM Evidence and the BMJ confirmed the results held consistently across all four countries — this wasn't a fluke in one setting.

The WHO has long endorsed integrated approaches to postpartum hemorrhage prevention in sub-Saharan Africa, but trials at this scale with this level of consistency are rare. Postpartum hemorrhage is the leading cause of maternal death globally, killing roughly 70,000 women a year, so a 60% reduction in severe cases is a genuinely significant finding with real-world implications for hospital protocols.

This claim spreads easily because it is good news — and good news in global health, especially about maternal mortality in Africa, travels fast among advocates, clinicians, and journalists. That's not a bad thing here. But it's worth knowing the specifics: the reduction applies to severe PPH outcomes in hospital settings using the full bundle. It doesn't mean the problem is solved, and scaling the approach to under-resourced clinics remains a challenge the researchers themselves flag.

Sources

  • WHO recommendations on uterotonics for postpartum haemorrhage prevention

    WHO has endorsed integrated approaches to postpartum hemorrhage prevention in sub-Saharan Africa, but specific trial details matching the claimed scale and countries require verification against primary literature.

  • E-MOTIVE Trial - The Lancet (2023)

    The E-MOTIVE trial, published in The Lancet in 2023, tested a bundled intervention for postpartum hemorrhage in Nigeria, Kenya, Tanzania, and South Africa, involving over 200,000 women, and found a significant reduction in severe postpartum hemorrhage (approximately 60% reduction in severe PPH outcomes).

  • University of Birmingham E-MOTIVE Trial Press Release

    The E-MOTIVE trial enrolled approximately 210,000 women across 78 hospitals in the four African countries and demonstrated a marked decrease in severe bleeding cases through an integrated bundle including early detection and treatment.

  • NEJM Evidence - E-MOTIVE trial coverage

    Independent analyses confirmed the E-MOTIVE bundle approach, combining uterotonic drugs, uterine massage, IV fluids, and examination, significantly reduced severe postpartum hemorrhage in the multi-country African trial.

  • BMJ News Report on E-MOTIVE Trial

    The BMJ reported the E-MOTIVE trial results showing the integrated care bundle reduced severe PPH by around 60% compared to standard care, with results consistent across all four participating countries.

TellWell AI

Related debunks